| Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy |
|
Annual Review of Pathology: Mechanisms of Disease |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Clonal Hematopoiesis and therapy related MDS/AML |
|
Best Practice & Research. Clinical Heamatology |
Myelodysplastic Syndromes (MDS) |
| Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery? |
|
Leukemia & Lymphoma |
Aplastic Anemia |
| Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria |
|
Leukemia & Lymphoma |
Aplastic Anemia |
| Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents |
|
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience |
|
Leukemia & Lymphoma |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options |
|
Cancer Management and Research |
Myelodysplastic Syndromes (MDS) |
| Clinical decision‐making and treatment of myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Clinical decision-making and treatment of myelodysplastic syndromes |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia |
|
Leukemia |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
